TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37121237
Drug: Aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100 mg tablet once per day)
Study: 37121237
Drug: Indobufen and
Normalized name: indobufen
DrugBank: Indobufen (DB12545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indobufen and Aspirin
Study: 37121390
Drug: Referral to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Referral to the Mid-Ohio Farmacy (weekly access to fresh produce)
Study: 37122050
Drug: Weight-based HFNC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-based HFNC (max flow of 2 L/kg per minute)
Study: 37122050
Drug: Standard HFNC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard HFNC (max flow of 8 L per minute)
Study: 37122809
Drug: SB2 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SB2 treatment in IFX-naïve patients
Study: 37122809
Drug: SB2 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SB2 treatment in IFX ref patients
Study: 37122809
Drug: SB2 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SB2 treatment in IFX bs patients
Study: 37124199
Drug: Machine learning-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Machine learning-based detection system for medication errors
Study: 37124726
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (TE), 75 mg intramuscularly/month for 6 months
Study: 37124726
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate (TU), 250 mg intramuscularly every 3 months for 6 months
Study: 37124732
Drug: ω3-LCPUFAs (500-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω3-LCPUFAs (500-mg soft capsules, 0.100 g/kg of body weight/day for three months)
Study: 37125397
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose vitamin D (5000 IU/day)
Study: 37125397
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose vitamin D (600 IU/day)
Study: 37125459
Drug: Daprodustat 4
Normalized name: daprodustat 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daprodustat 4 mg tablets manufactured via twin-screw wet granulation (process 1)
Study: 37125459
Drug: Daprodustat tablets
Normalized name: daprodustat
DrugBank: Daprodustat (DB11682)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Daprodustat tablets manufactured via process 1 (1, 2, 4, 6, and 8 mg)
Study: 37125459
Drug: Daprodustat tablets
Normalized name: daprodustat
DrugBank: Daprodustat (DB11682)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Daprodustat tablets manufactured via process 2 (1, 2, 4, 6, and 8 mg)
Study: 37125500
Drug: L-citrulline +
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-citrulline + Glutathione (Setria Performance Blend: SPB; L-citrulline [2 g] + glutathione [200 mg], 6 capsules)
Study: 37125500
Drug: Placebo (PL;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PL; 3.1 g cellulose, 6 capsules)
Study: 37125884
Drug: Psychosocial stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosocial stimulation intervention consisting of weekly play sessions at home for 9 months, along with iron treatment for 6 months for IDA group.
Study: 37126069
Drug: Positron emission
Normalized name: propofol lipid emulsion Injection [Propoven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positron emission tomography/CT after intravenous administration of 296±20% MBq
Study: 37126332
Drug: Xuebijing injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuebijing injection (100 mL, intravenous infusion every 12 hours for 5 days)
Study: 37126332
Drug: Placebo (volume-matched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (volume-matched saline, intravenous infusion every 12 hours for 5 days)
Study: 37126338
Drug: Multimodal transitional
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multimodal transitional care intervention including systematic medication reconciliation, a 15-minute patient education session with teach-back, a planned first follow-up visit with their primary care physician, and postdischarge follow-up telephone calls at 3 and 14 days.
Study: 37126399
Drug: Intranasal testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal testosterone gel 11 mg 3 times daily
Study: 37126399
Drug: Intramuscular testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular testosterone cypionate 200 mg every 2 weeks
Study: 37126739
Drug: Omega-3 supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 supplementation (600 mg EPA and 300 mg DHA, twice daily)
Study: 37126770
Drug: Lenalidomide (regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide (regimen A, low-dose 20 mg/m2)
Study: 37127045
Drug: Fractional dose
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional dose (one-fifth of the standard dose) of 17D-213 yellow fever vaccine
Study: 37127047
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of 17D-213 yellow fever vaccine
Study: 37127047
Drug: Fractional dose
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional dose (one-fifth) of 17D-213 yellow fever vaccine
Study: 37127210
Drug: Advanced oral
Normalized name: Imodium Advanced Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advanced oral hygiene regimen (antibacterial mouth wash, dental floss, antibacterial toothpaste, power toothbrush, intensive oral hygiene education)
Study: 37127210
Drug: Usual oral
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual oral hygiene care (standard oral home care instructions and regimen)
Study: 37127210
Drug: Advanced oral
Normalized name: Imodium Advanced Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advanced oral hygiene regimen
Study: 37127210
Drug: Usual oral
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual oral hygiene care
Study: 37127210
Drug: Advanced oral
Normalized name: Imodium Advanced Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advanced oral hygiene regimen among unemployed participants with less favorable socioeconomic status
Study: 37127210
Drug: Usual oral
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual oral hygiene care among unemployed participants with less favorable socioeconomic status
Study: 37127526
Drug: Sabin strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sabin strain inactivated poliovirus vaccine (sIPV)
Study: 37127526
Drug: Wild strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wild strain poliovirus vaccine (wIPV)
Study: 37127558
Drug: vonoprazan 20
Normalized name: vonoprazan 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: vonoprazan 20 mg for 4-8 weeks, then 10 mg for maintenance
Study: 37127558
Drug: lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lansoprazole 30 mg for 4-8 weeks, then 15 mg for maintenance
Study: 37127632
Drug: HEMO2life® (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEMO2life® (1 g/l preservation solution)
Study: 37127632
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (routine preservation solution)
Study: 37127657
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg naldemedine daily for 12 months
Study: 37127754
Drug: CBP/p300 HAT
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBP/p300 HAT inhibitors
Study: 37127754
Drug: Investigational KAT6A/B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational KAT6A/B HAT inhibitor
Study: 37129110
Drug: Recast therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recast therapy embedded in a first-grade science curriculum
Study: 37129110
Drug: Recast therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recast therapy
Study: 37129155
Drug: Capecitabine maintenance
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine maintenance after XELOX chemotherapy
Study: 37129155
Drug: Observation after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation after XELOX chemotherapy
Study: 37129197
Drug: Selinexor in
Normalized name: Product containing selinexor in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selinexor in combination with pembrolizumab
Study: 37129455
Drug: LCL161 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCL161 plus oral topotecan
Study: 37129584
Drug: Ropeginterferon α-2b,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropeginterferon α-2b, starting dose of 250 μg, increasing to 350 μg at week 2 and 500 μg at week 4, with adjustments based on tolerability.
Study: 37130017
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg every 3 weeks for up to 35 cycles (∼2 years)
Study: 37130111
Drug: Continuous positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous positive airway pressure (CPAP) therapy for moderate-to-severe SRBDs
Study: 37130158
Drug: Control (continued
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (continued systemic chemotherapy)
Study: 37130329
Drug: Minimally invasive
Normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimally invasive surgery for gastrointestinal cancer treatment
Study: 37130668
Drug: Usual care,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care, plus weekly text messages to encourage walking and paper handouts
Study: 37130681
Drug: T2DM remission
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: T2DM remission defined as glycated haemoglobin (HbA1c) <6.0% without medications
Study: 37130685
Drug: Rapid serological
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid serological test (RST) for SARS-CoV-2 antibodies (OrientGene)
Study: 37131014
Drug: Metformin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin + AC-T
Study: 37131154
Drug: Standard immunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard immunotherapy (IO) regimen administered every 3 months
Study: 37131154
Drug: Reduced intensity
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced intensity dose of IO administered every 3 months
Study: 37131191
Drug: Bupivacaine dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine dose adjusted by height-based dosing algorithm
Study: 37131191
Drug: Constant bupivacaine
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant bupivacaine dose
Study: 37131265
Drug: Benralizumab (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benralizumab (30 mg subcutaneous doses at 4-week intervals)
Study: 37131531
Drug: Intradermal acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal acupuncture (IDA)
Study: 37131659
Drug: COVID-19 convalescent
Normalized name: COVID-19 convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-19 convalescent plasma (CCP) with high antibody levels transfused early (symptom onset within 5 days)
Study: 37131659
Drug: COVID-19 convalescent
Normalized name: COVID-19 convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-19 convalescent plasma (CCP) with low antibody levels or control plasma
Study: 37131755
Drug: Motivational Interviewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational Interviewing (MI) intervention focusing on PrEP use and concomitant stimulant use or condomless anal sex
Study: 37831485
Drug: Contingency Management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contingency Management (CM) intervention with financial incentives for documented evidence of PrEP clinical evaluation and filling a PrEP prescription
Study: 37131861
Drug: PHH-1V booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHH-1V booster vaccine
Study: 37131861
Drug: BNT162b2 booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 booster vaccine
Study: 37132281
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy with gemcitabine 1000 mg/m² and nab-paclitaxel
Study: 37133249
Drug: Historical standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historical standard of care (chemotherapy)
Study: 37133584
Drug: Temporary interruption
Normalized name: Sus scrofa temporal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temporary interruption of adjuvant endocrine therapy to attempt pregnancy
Study: 37133585
Drug: FTD-TPI plus
Normalized name: TPI-287
DrugBank: TPI-287 (DB17168)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTD-TPI plus bevacizumab (combination group)
Study: 37133647
Drug: Guideline-recommended medications
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Guideline-recommended medications (ACE inhibitors)
Study: 37133647
Drug: Guideline-recommended medications
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Guideline-recommended medications (Angiotensin receptor blockers)
Study: 37133647
Drug: Guideline-recommended medications
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Guideline-recommended medications (Mineralocorticoid receptor antagonists)
Study: 37133673
Drug: High-dose dual
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dual therapy (HDDT): rabeprazole 20 mg and amoxicillin 750 mg q.i.d for 14 days (n=122)
Study: 37133673
Drug: Rabeprazole-containing hybrid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole-containing hybrid therapy (HT): rabeprazole 20 mg and amoxicillin 1 g b.i.d. for 7 days, followed by rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg b.i.d. for 7 days (n=121)
Study: 37133829
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (systolic BP target < 120 mm Hg)
Study: 37133829
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (systolic BP target < 140 mm Hg)
Study: 37134108
Drug: Avasimibe (ACAT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avasimibe (ACAT inhibitor)
Study: 37134130
Drug: Fixed-schedule rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fixed-schedule rituximab infusion (500 mg)
Study: 37134130
Drug: Tailored-infusion regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored-infusion regimen of rituximab
Study: 37134130
Drug: Low rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Low rituximab plasma concentration at 3 months (CM3 <4 μg/ml)
Study: 37134230
Drug: Conventional compression
Normalized name: oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional compression dressing therapy
Study: 37137304
Drug: ChemoID assay-guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChemoID assay-guided chemotherapy
Study: 37137304
Drug: Physician-chosen chemotherapy
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Physician-chosen chemotherapy
Study: 37137527
Drug: Once-weekly subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly subcutaneous semaglutide
Study: 37137553
Drug: BCMA CAR-T
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCMA CAR-T therapy
Study: 37137617
Drug: RBC folate
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RBC folate deficiency (<305 nmol/L) and insufficiency (<748 nmol/L)
Study: 37138460
Drug: ChAdOx1 nCoV-19
Normalized name: ChAdOx1 nCoV-19
DrugBank: AstraZeneca COVID-19 Vaccine (DB15656)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAdOx1 nCoV-19 vaccine trial participation
Study: 37138473
Drug: Pegloticase (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegloticase (8 mg intravenous every 2 weeks)
Study: 37138742
Drug: New Echinacea
Normalized name: Echinacea
DrugBank: Echinacea (DB14240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: New Echinacea formulation
Study: 37138742
Drug: Conventional Echinacea
Normalized name: Echinacea
DrugBank: Echinacea (DB14240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Echinacea formulation
Study: 37139775
Drug: Modified constraint-induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified constraint-induced movement therapy (80 hours) and bimanual intensive therapy (20 hours)
Study: 37139775
Drug: Bimanual intensive
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bimanual intensive therapy (80 hours) and modified constraint-induced movement therapy (20 hours)
Study: 37139775
Drug: Modified constraint-induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified constraint-induced movement therapy (20 hours)
Study: 37139775
Drug: Modified constraint-induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified constraint-induced movement therapy (80 hours)
Study: 37139775
Drug: Bimanual intensive
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bimanual intensive therapy (20 hours)
Study: 37140460
Drug: e-CBT and
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: e-CBT and treatment as usual (TAU)
Study: 37140493
Drug: Buprenorphine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine administration initiated by practitioners
Study: 37140493
Drug: 30-day treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30-day treatment engagement
Study: 37140493
Drug: Attendance at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attendance at treatment visits
Study: 37140517
Drug: 1:10,000-diluted topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1:10,000-diluted topical epinephrine
Study: 37140558
Drug: HilleVax bivalent
Normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HilleVax bivalent virus-like particle (VLP) vaccine candidate (HIL-214) with 15/15 μg of GI.1/GII.4c genotype VLPs
Study: 37140558
Drug: HilleVax bivalent
Normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HilleVax bivalent virus-like particle (VLP) vaccine candidate (HIL-214) with 15/50 μg of GI.1/GII.4c genotype VLPs
Study: 37140558
Drug: HilleVax bivalent
Normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HilleVax bivalent virus-like particle (VLP) vaccine candidate (HIL-214) with 50/50 μg of GI.1/GII.4c genotype VLPs
Study: 37140558
Drug: HilleVax bivalent
Normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HilleVax bivalent virus-like particle (VLP) vaccine candidate (HIL-214) with 50/150 μg of GI.1/GII.4c genotype VLPs
Study: 37140602
Drug: BI 836880
Normalized name: BI-836880
DrugBank: BI-836880 (DB17484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 836880 monotherapy (720 mg Q3W)
Study: 37140602
Drug: BI 836880
Normalized name: BI-836880
DrugBank: BI-836880 (DB17484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 836880 (720 mg Q3W) plus ezabenlimab (240 mg Q3W)
Study: 37140705
Drug: Vedolizumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vedolizumab (3 doses during induction phase)
Study: 37140727
Drug: Cotadutide (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotadutide (single dose)
Study: 37140904
Drug: Bacterial decolonization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacterial decolonization (BD) using intranasal mupirocin ointment twice daily and chlorhexidine body cleanser once daily for 5 days prior to RT and repeated for 5 days every 2 weeks through RT.
Study: 37141260
Drug: Home-based inspiratory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based inspiratory muscle training (IMT) using 30% of maximal inspiratory pressure, increasing by 10% weekly, 30 repetitions, twice a day for 6 weeks.
Study: 37141544
Drug: Nivolumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab plus platinum-doublet chemotherapy
Study: 37141544
Drug: Platinum-doublet chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-doublet chemotherapy alone
Study: 37141764
Drug: GLYT1 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GLYT1 inhibitor (PF-03463275) 40 or 60 mg twice daily with cognitive training (CT)
Study: 37141828
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg intravenously every 3 weeks for ≤35 cycles
Study: 37141847
Drug: Avelumab 800
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab 800 mg every 2 weeks (Q2W) and axitinib 5 mg orally two times daily
Study: 37142308
Drug: Psilocybin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin (15 mg)
Study: 37142308
Drug: Psilocybin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin (15 mg and 25 mg) with psychotherapy